← Our News

Research & clinical trials, Information & guidance, Charity news & media, Policy & advocacy

Positive Development in NICE Cabozantinib Appraisal Appeal

By Beth Chesser

Posted 3 months ago

11/08/2026 11am

Listen to this article

Neuroendocrine Cancer UK welcomes the outcome of the recent appeal relating to NICE’s appraisal of cabozantinib for advanced neuroendocrine tumours. 

The NICE appeal panel has upheld three key appeal points while dismissing the remaining grounds of appeal. As a result, the appraisal has been remitted back to the NICE appraisal committee for further consideration. 

This is an encouraging development for the neuroendocrine cancer community. While the appeal outcome does not mean cabozantinib has been recommended for routine NHS use, it ensures that important clinical evidence will receive further scrutiny before a final decision is made. 

Next Steps 

The appraisal will now return to NICE Technology Appraisal Committee, which is scheduled to meet on 9 September 2026. 

Clinical and patient experts who contributed to the original appraisal process will be invited to participate in the post-appeal meeting. Members of the public will also be able to observe the meeting by registering through NICE once the agenda and access details are published. 

It is important to note that this is not an opportunity to submit new evidence. Instead, the committee has been asked to reconsider and further evaluate the existing evidence, particularly in relation to the survival benefit associated with cabozantinib. 

Why This Matters 

For people living with advanced neuroendocrine tumours, access to new treatment options remains a significant unmet need. The appeal panel’s decision recognises the importance of fully evaluating the evidence relating to cabozantinib’s potential benefits and provides an opportunity for these data to be reconsidered as part of the NICE appraisal process. 

Neuroendocrine Cancer UK will continue to monitor developments closely and will keep the community updated as further information becomes available following the September committee meeting. 

Further Information: The full appeal decision and appraisal documents are available on the NICE website: https://www.nice.org.uk/guidance/indevelopment/gid-ta11613  

Catch up on the latest news, stories and updates

Angela

Patient Ambassador

Angela became an Ambassador in 2026.

/* ---- merged from snippet 271: Moth clipping path ---- */ /* ---- merged from snippet 312: Fancy text ---- */